JPMorgan analyst Lisa Gill raised the firm’s price target on Concentra (CON) to $30 from $29 and keeps an Overweight rating on the shares.

Concentra®, the nation’s leader in occupational medicine, today announced the opening of a new medical center in Waukegan, ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Acelyrin (NASDAQ:SLRN) stock in focus as the company adopts a poison pill to counter rapid stock acquisition by Tang Capital Partners. Read more here.

Bank of New York Mellon Corp increased its stake in shares of Concentra Group Holdings Parent, Inc. (NYSE:CON – Free Report) by 1,339.5% during the 4th quarter, Holdings Channel.com reports. The firm ...

Wells Fargo lowered the firm’s price target on Concentra (CON) to $25 from $27 and keeps an Overweight rating on the shares. The firm is also ...

Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...

La 27ma edizione del festival sui diritti umani presenterà 84 documentari, 11 film di finzione e nove esperienze immersive in ...

Concentra acquired five clinics in Miami-Dade County. The clinics specialize in work injury care and drug testing. OM ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

ADDISON, Texas, March 10, 2025--(BUSINESS WIRE)--Concentra ®, the nation’s leader in occupational medicine, today announced ...